Embark Veterinary is a startup in the field of genomics and biotechnology. His latest research is focused on the dog: mainly on the processing of the genetic profile to increase the life years of man’s best friend.
The company was founded in 2015 and is based in Boston. Embark Veterinaryoffers a DNA test for pets that identifies its specific origin and determines the health conditions to take into account. Thus, future dog illnesses can be anticipated before they occur and thus increase their life expectancy.
This test can show that a healthy dog has a high percentage of breaking bones, so it will be important to watch your weight and diet.
Another possible disease that can be detected is hyperuricosuria, which occurs when there are high levels of uric acid in the body, which can lead to kidney or bladder stones. Again, control the animal’s diet It will be important to avoid the appearance of this and other diseases and to extend the life expectancy of the pet.
Embark Veterinary offers a DNA test to detect early illness in pets. Photo: Instagram / @ embarkvet
The test is called Breed ID and at this moment its price is 129 dollars, about 23 thousand pesos at the exchange of the day.
The company is currently considering opening up to the international market after the latest advances and the large financial investment made by Vision Found.
But from what its founders say, the brothers Ryan and Adam BoykoIt is a project with a future. “The issue of mortality, due to the pandemic, made families realize that they want their dogs around for as long as possible, “Boyko acknowledged to Bloomberg.
Also, and as published by this news agency, Embark Veterinary revenues increased 235% last year and is close to exceeding $ 100 million this year.
A luxury investor
Masayoshi Son, the businessman and owner of Softbank, joined the project because he was seduced by the plan to extend the life of the dogs in the next decade.
With a strong economic commitment, the Japanese investor led a financing round of 75 million dollars for the company. Fact that has caused Embark Veterinary’s valuation to skyrocket to 700 million.
The Japanese businessman owns shares in companies of the size of Netflix, Amazon or Tesla although it remains to be seen if he was successful with this new economic adventure.
After all, it would not be the first time that an injection in a startup has generated losses for Son. It is the example of Uber and WeWork, these two bets cost him $ 16 million in losses.
With information from La Vanguardia.